• No results found

[PDF] Top 20 The Effectiveness of High Dose Chemotherapy and Autologous Stem Cell Transplantation in the Treatment of Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

Has 10000 "The Effectiveness of High Dose Chemotherapy and Autologous Stem Cell Transplantation in the Treatment of Non-Hodgkin’s Lymphoma and Hodgkin’s Disease" found on our website. Below are the top 20 most common "The Effectiveness of High Dose Chemotherapy and Autologous Stem Cell Transplantation in the Treatment of Non-Hodgkin’s Lymphoma and Hodgkin’s Disease".

The Effectiveness of High Dose Chemotherapy and Autologous Stem Cell Transplantation in the Treatment of Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

The Effectiveness of High Dose Chemotherapy and Autologous Stem Cell Transplantation in the Treatment of Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

... line chemotherapy and 49 (64%) of these were randomised to either standard salvage therapy with DHAP (27) or high dose chemotherapy with Busulphan, Etoposie, Cytarabie, Melphalan (BEAC) + ... See full document

70

The Effectiveness of High Dose Chemotherapy and Bone Marrow/Autologous Stem Cell Transplantation in the Treatment of Multiple Myeloma

The Effectiveness of High Dose Chemotherapy and Bone Marrow/Autologous Stem Cell Transplantation in the Treatment of Multiple Myeloma

... indolent disease where close observation is ...of high dose corticosteroids (vincristine/doxorubicin/dexamethasone - VAD, vincristine/adriamycin/methylprednisolone - VAMP) result in higher response ... See full document

49

High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non Hodgkin's Lymphoma: an Eight Year Experience

High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non Hodgkin's Lymphoma: an Eight Year Experience

... tory disease is very ...new treatment strategy is needed for ...allogeneic stem cell transplantation even though the positive result in the T-NK cell lymphoma case had ... See full document

10

<p>rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma</p>

<p>rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin&rsquo;s lymphoma</p>

... collected cell number that reached the minimum cell number threshold (2×10 6 CD34+ cells/kg) for transplantation received the subsequent high-dose che- motherapy and autologous ... See full document

7

Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study

Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study

... induction chemotherapy, before the first and second HDCT/auto- SCT, every 3 months for the first year after the second HDCT/auto-SCT, every 4 months for the second year, every 6 months for the third year, and ... See full document

11

Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non Hodgkin lymphoma

Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non Hodgkin lymphoma

... optimal stem cell transplantation (SCT) con- ditioning therapy for relapsed/refractory non- Hodgkin lymphoma (NHL) is not clearly ...had chemotherapy-resistant ... See full document

9

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

... stable disease following CVP induction chemotherapy were randomized to either rituximab maintenance therapy or standard ...induction chemotherapy without the inclusion of rituximab during ... See full document

9

Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma

Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma

... Abstract: Hodgkin lymphoma (HL) represents ~11% of all lymphoma ...This disease occurs in young adults, but also affects people over 55 years of ...initial treatment and 10%–30% of ... See full document

5

Management of patients with non-Hodgkin&amp;rsquo;s lymphoma: focus on adoptive T-cell therapy

Management of patients with non-Hodgkin&rsquo;s lymphoma: focus on adoptive T-cell therapy

... with high-dose chemo- therapy, as well as recipients of organ-transplant or hematopoietic stem cells, have a higher risk of developing ...Burkitt’s lymphoma, nasal ... See full document

9

A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin

A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin

... Abstract: Hodgkin lymphoma (HL) is a highly curable hematologic malignancy, and ~70% of cases can be cured with combination chemotherapy with or without ...resistant disease have a cure rate ... See full document

9

Reduced intensity treatment in early-stage Hodgkin&amp;rsquo;s lymphoma

Reduced intensity treatment in early-stage Hodgkin&rsquo;s lymphoma

... Hodgkin’s lymphoma was first described by Thomas Hodgkin in the 1830s in a manu- script titled “Some Morbid Appearances of the Absorbent Glands and ...fatal disease it is now one of the most curable ... See full document

9

The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis

The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis

... prior treatment history]; intervention and comparator (if applicable); intervention(s) [drugs, doses, number of cycles, administration, concomitant therapy], methods of HSCT [including donor source and ... See full document

7

Cancer risk in microscopic colitis: a retrospective cohort study

Cancer risk in microscopic colitis: a retrospective cohort study

... Crohn’s disease [12, 14, ...celiac disease characterized by persistent lymphocytosis and villous blunting with enteropathic T-cell lymphoma, and pri- mary sclerosing cholangitis with ... See full document

7

Bendamustine in the treatment of non-Hodgkin&amp;rsquo;s lymphomas

Bendamustine in the treatment of non-Hodgkin&rsquo;s lymphomas

... have disease considered refractory to their last chemotherapy regimen (that is, no CR or PR) was 64%, including 6% CR, and 88% for those known to have chemosensitive disease, with 30% ... See full document

11

Update on treatment of follicular non-Hodgkin&amp;rsquo;s lymphoma: focus on potential of bortezomib

Update on treatment of follicular non-Hodgkin&rsquo;s lymphoma: focus on potential of bortezomib

... follicular lymphoma, with promising preclinical data and efficacy in patients with other hematological ...the treatment of non-Hodgkin’s ...follicular lymphoma varied greatly (16%–41%), with ... See full document

13

Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias

Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias

... Burkitt cell ALL is characterized by the morphology of blast cells, the presence of monoclonal surface immunoglobulins, and by chromosomal translocations [t(8;14)(q24;q32), t(2;8) (p12;q24) or t(8;22)(q24;q11)] ... See full document

20

Kikuchi-Fujimoto disease: a case report and the evaluation of diagnostic procedures

Kikuchi-Fujimoto disease: a case report and the evaluation of diagnostic procedures

... cat-scratch disease and tuberculous ...and non-Hodgkin lymphoma. After Kikuchi-Fujimoto disease was identified, the patient was managed with symptomatic ...Kikuchi-Fujimoto ... See full document

5

IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy

IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy

... Eleven patients underwent HDT/ASCT, as part of their front line therapy, five patients received single and six tandem ASCT. Six out of 11 patients received induc- tion chemotherapy including thalidomide and/or ... See full document

5

Original Article Comparison of therapeutic efficacy and complications between autologous stem cell transplantation and chemotherapy for large B-cell lymphoma: a meta-analysis

Original Article Comparison of therapeutic efficacy and complications between autologous stem cell transplantation and chemotherapy for large B-cell lymphoma: a meta-analysis

... Garciaz S, Touzeau C, Chaleteix C, Fermand JP, Loiseau HA, Facon T, Attal M, Moreau P; Intergroupe Francophone du Myélome ...single autologous stem cell trans- plantation in multiple ... See full document

9

&lt;p&gt;Abdominal Lymphocyte-Depleted Hodgkin Lymphoma: A Rare Presentation&lt;/p&gt;

<p>Abdominal Lymphocyte-Depleted Hodgkin Lymphoma: A Rare Presentation</p>

... extranodal disease, high ESR, involvement of three or more lymph node areas, and higher IPS; in addition, organ involvement of bone marrow and liver was also more ...of Hodgkin lymphoma is ... See full document

5

Show all 10000 documents...